A team of chemists in SU's College of Arts and Scientists has used a temperature-sensitive polymer to regulate DNA interactions in both a DNA-mediated assembly system and a DNA-encoded drug-delivery system.

Japanese researchers report that incorporating magnetic nanoparticles and an anticancer drug into crosslinked polymer nanofibers presents a twofold treatment for fighting cancer with diminished side effects.

Re-routing anti-cancer drugs to the "power plants" that make energy to keep cells alive is a promising but long-neglected approach to preventing emergence of the drug-resistant forms of cancer—source of ...

Scientists at Karolinska Institutet in Sweden describe in a new study how so-called DNA origami can enhance the effect of certain cytostatics used in the treatment of cancer. With the aid of modern nanotechnology, scientists ...

In a nanotechnology two-for-one, researchers at the Johns Hopkins University Center of Cancer Nanotechnology Excellence (Hopkins CCNE) have created a polymer nanoparticle that overcomes tumor resistance to the common anticancer ...

One of the ways in which cancer cells evade anticancer therapy is by producing a protein that pumps drugs out of the cell before these compounds can exert their cell-killing effects. A research team at Northwestern University ...

(PhysOrg.com) -- An ideal treatment for lung cancer would be one that could be inhaled deep into lung tissue where it would deliver tumor-killing agents that would then largely stay in the lungs, avoiding the toxicities that ...

Radiation and chemotherapy are common partners in anticancer therapy for solid tumors, but too often, the combined side effects associated with each mode of therapy can limit how aggressively oncologists can treat their patients. ...

The standard approach to cancer therapy today is to mix and match chemotherapy drugs in order to attack tumors in multiple ways. Now, two separate teams of investigators have demonstrated that using nanoparticles to deliver ...

In the past 40 years, scientists have learned a great deal about how cells become cancerous. Some of that knowledge has translated to new treatments, but most of the time doctors are forced to rely on standard ch ...

Doxorubicin

Doxorubicin INN ( /ˌdɒksəˈruːbəsɪn/; trade name Adriamycin; also known as hydroxydaunorubicin) is a drug used in cancer chemotherapy. It is an anthracycline antibiotic, closely related to the natural product daunomycin, and like all anthracyclines, it works by intercalating DNA.

Doxorubicin is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas.

The drug is administered intravenously, in the form of hydrochloride salt. It may be sold under the brand names Adriamycin PFS, Adriamycin RDF, or Rubex. Doxorubicin is photosensitive, and containers are often covered by an aluminum bag and/or brown wax paper to prevent light from affecting it.

The molecule was originally isolated in the 1950s from bacteria found in soil samples taken from Castel del Monte, an Italian castle.